Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models
Microglial dysfunction is a key pathological feature of Alzheimer's disease (AD), but little is known about proteome-wide changes in microglia during the course of AD and their functional consequences. Here, we performed an in-depth and time-resolved proteomic characterization of microglia in t...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2020-06-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/54083 |
id |
doaj-de74f8be04d64e159352e6741a9c1929 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Laura Sebastian Monasor Stephan A Müller Alessio Vittorio Colombo Gaye Tanrioever Jasmin König Stefan Roth Arthur Liesz Anna Berghofer Anke Piechotta Matthias Prestel Takashi Saito Takaomi C Saido Jochen Herms Michael Willem Christian Haass Stefan F Lichtenthaler Sabina Tahirovic |
spellingShingle |
Laura Sebastian Monasor Stephan A Müller Alessio Vittorio Colombo Gaye Tanrioever Jasmin König Stefan Roth Arthur Liesz Anna Berghofer Anke Piechotta Matthias Prestel Takashi Saito Takaomi C Saido Jochen Herms Michael Willem Christian Haass Stefan F Lichtenthaler Sabina Tahirovic Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models eLife Alzheimer's disease microglia proteomic signatures neuroinflammation phagocytosis |
author_facet |
Laura Sebastian Monasor Stephan A Müller Alessio Vittorio Colombo Gaye Tanrioever Jasmin König Stefan Roth Arthur Liesz Anna Berghofer Anke Piechotta Matthias Prestel Takashi Saito Takaomi C Saido Jochen Herms Michael Willem Christian Haass Stefan F Lichtenthaler Sabina Tahirovic |
author_sort |
Laura Sebastian Monasor |
title |
Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models |
title_short |
Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models |
title_full |
Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models |
title_fullStr |
Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models |
title_full_unstemmed |
Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models |
title_sort |
fibrillar aβ triggers microglial proteome alterations and dysfunction in alzheimer mouse models |
publisher |
eLife Sciences Publications Ltd |
series |
eLife |
issn |
2050-084X |
publishDate |
2020-06-01 |
description |
Microglial dysfunction is a key pathological feature of Alzheimer's disease (AD), but little is known about proteome-wide changes in microglia during the course of AD and their functional consequences. Here, we performed an in-depth and time-resolved proteomic characterization of microglia in two mouse models of amyloid β (Aβ) pathology, the overexpression APPPS1 and the knock-in APP-NL-G-F (APP-KI) model. We identified a large panel of Microglial Aβ Response Proteins (MARPs) that reflect heterogeneity of microglial alterations during early, middle and advanced stages of Aβ deposition and occur earlier in the APPPS1 mice. Strikingly, the kinetic differences in proteomic profiles correlated with the presence of fibrillar Aβ, rather than dystrophic neurites, suggesting that fibrillar Aβ may trigger the AD-associated microglial phenotype and the observed functional decline. The identified microglial proteomic fingerprints of AD provide a valuable resource for functional studies of novel molecular targets and potential biomarkers for monitoring AD progression or therapeutic efficacy. |
topic |
Alzheimer's disease microglia proteomic signatures neuroinflammation phagocytosis |
url |
https://elifesciences.org/articles/54083 |
work_keys_str_mv |
AT laurasebastianmonasor fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels AT stephanamuller fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels AT alessiovittoriocolombo fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels AT gayetanrioever fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels AT jasminkonig fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels AT stefanroth fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels AT arthurliesz fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels AT annaberghofer fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels AT ankepiechotta fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels AT matthiasprestel fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels AT takashisaito fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels AT takaomicsaido fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels AT jochenherms fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels AT michaelwillem fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels AT christianhaass fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels AT stefanflichtenthaler fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels AT sabinatahirovic fibrillarabtriggersmicroglialproteomealterationsanddysfunctioninalzheimermousemodels |
_version_ |
1721458309286854656 |
spelling |
doaj-de74f8be04d64e159352e6741a9c19292021-05-05T21:11:05ZengeLife Sciences Publications LtdeLife2050-084X2020-06-01910.7554/eLife.54083Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse modelsLaura Sebastian Monasor0https://orcid.org/0000-0001-7864-7400Stephan A Müller1https://orcid.org/0000-0003-3414-307XAlessio Vittorio Colombo2Gaye Tanrioever3Jasmin König4Stefan Roth5Arthur Liesz6Anna Berghofer7Anke Piechotta8Matthias Prestel9Takashi Saito10Takaomi C Saido11Jochen Herms12Michael Willem13Christian Haass14Stefan F Lichtenthaler15https://orcid.org/0000-0003-2211-2575Sabina Tahirovic16https://orcid.org/0000-0003-4403-9559German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Graduate School of Systemic Neuroscience, Ludwig-Maximilians-University, Munich, GermanyGerman Center for Neurodegenerative Diseases (DZNE), Munich, GermanyGerman Center for Neurodegenerative Diseases (DZNE), Munich, GermanyGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany; Department of Cellular Neurology, Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, GermanyGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Faculty of Chemistry, Technical University of Munich, Garching, GermanyInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU, Munich, GermanyInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, GermanyNeuroproteomics, School of Medicine, Klinikum Rechts der Isar, Technical University, Munich, GermanyDepartment of Molecular Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology, Halle, GermanyInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU, Munich, GermanyLaboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science Institute, Wako, Japan; Department of Neurocognitive Science, Nagoya City University Graduate School of Medical Science, Nagoya, JapanLaboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science Institute, Wako, JapanGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universität München, Munich, GermanyBiomedical Center (BMC), Ludwig-Maximilians Universität München, Munich, GermanyGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; Biomedical Center (BMC), Ludwig-Maximilians Universität München, Munich, GermanyGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; Neuroproteomics, School of Medicine, Klinikum Rechts der Isar, Technical University, Munich, GermanyGerman Center for Neurodegenerative Diseases (DZNE), Munich, GermanyMicroglial dysfunction is a key pathological feature of Alzheimer's disease (AD), but little is known about proteome-wide changes in microglia during the course of AD and their functional consequences. Here, we performed an in-depth and time-resolved proteomic characterization of microglia in two mouse models of amyloid β (Aβ) pathology, the overexpression APPPS1 and the knock-in APP-NL-G-F (APP-KI) model. We identified a large panel of Microglial Aβ Response Proteins (MARPs) that reflect heterogeneity of microglial alterations during early, middle and advanced stages of Aβ deposition and occur earlier in the APPPS1 mice. Strikingly, the kinetic differences in proteomic profiles correlated with the presence of fibrillar Aβ, rather than dystrophic neurites, suggesting that fibrillar Aβ may trigger the AD-associated microglial phenotype and the observed functional decline. The identified microglial proteomic fingerprints of AD provide a valuable resource for functional studies of novel molecular targets and potential biomarkers for monitoring AD progression or therapeutic efficacy.https://elifesciences.org/articles/54083Alzheimer's diseasemicrogliaproteomic signaturesneuroinflammationphagocytosis |